Who
Annie Yoshiyama
SVP, Finance
Company insider
Files Form 4 as: SVP, Finance, Allogene Therapeutics; Senior VP, Finance and CAO, Tricida.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $72K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Dec 2020
- Last trade
- 21 Apr 2026
- Last filed
- 23 Apr 2026
Companies traded
Activity over time
1 Apr 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Apr 2026filed 23 Apr 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K9,586 at $2.31 | filing |
| 21 Apr 2026filed 23 Apr 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K9,586 at $2.31 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1674,167 at $1.72 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —179,691 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,827 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —179,691 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,827 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,1674,167 at $1.72 | filing |
| 21 Apr 2025filed 23 Apr 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K9,601 at $1.41 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —128,093 at $0.00 | filing |
| 24 Jan 2025filed 28 Jan 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —36,232 at $0.00 | filing |
| 5 Aug 2022filed 9 Aug 2022 | Tricidaoption or derivative | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 28 Feb 2022filed 2 Mar 2022 | Tricidaoption or derivative | SEC FORM 4 Code A | —86,000 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code A | —9,251 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code A | —2,750 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code A | —6,042 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code A | —3,959 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Tricidaoption or derivative | SEC FORM 4 Code D | —4,000 at $0.00 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026Head to Head Comparison: Generate Biomedicines (NASDAQ:GENB) vs. Allogene Therapeutics (NASDAQ:ALLO)ALLO · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Annie Yoshiyama; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.